During the past decade, Universitätsklinikum Gießen und Marburg GmbH; Neurologie conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 1 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Gießen und Marburg GmbH; Neurologie" are "Multiple Sclerosis, Primary Progressive" (1 trials) and "Relapsing Multiple Sclerosis" (1 trials). Many other conditions were trialed in "Universitätsklinikum Gießen und Marburg GmbH; Neurologie" in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Gießen und Marburg GmbH; Neurologie" are "Drug" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Fenebrutinib" (1 trials), "Ocrelizumab" (1 trials) and "Teriflunomide" (1 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Gießen und Marburg GmbH; Neurologie" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Universitätsklinikum Gießen und Marburg GmbH; Neurologie". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Universitätsklinikum Gießen und Marburg GmbH; Neurologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Gießen und Marburg GmbH; Neurologie, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".